RRML - The metabolic control and laboratory evaluation in patients with type 2 diabetes during the COVID-19 pandemic and the impact of telemedicine: a single-center experience
AMLR

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Română English

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Advanced search

Top 10 downloaded articles
- April 2024 -
 
A comprehensive review of Prof... 25
Recomandarea comună EFLM-COLA... 15
Anti-thyroid peroxidase (TPO) ... 11
Understanding the key differen... 10
Monocyte to high-density lipop... 10
Romanian Review of Laboratory ... 7
Understanding the pathogenesis... 7
Predictive value of expression... 7
Approaching Risk Management in... 6
Function of the S1P pathway in... 6

Log in

Concept, Design & Programming
Dr. Adrian Man
   
 
Nr. 31(1)/2023 DOI:10.2478/rrlm-2023-0002
XML
TXT

Research article

The metabolic control and laboratory evaluation in patients with type 2 diabetes during the COVID-19 pandemic and the impact of telemedicine: a single-center experience

Corina Roxana Onea, Ákos Erőss, Andrada Larisa Roiban, Simona Cernea

Correspondence should be addressed to: Simona Cernea

Abstract:

Objective: The study aimed to evaluate the metabolic control during the COVID-19 pandemic in subjects with type 2 diabetes mellitus (T2DM) and whether care through telemedicine significantly impacted it. Material and methods: This was a retrospective study for which three time-periods were prespecified: the COVID-19 pandemic period, pre-COVID-19 period, and before pre-COVID-19. The following information were collected: anthropometric and laboratory parameters (glycated hemoglobin (HbA1c), blood glucose, lipid profile, creatinine, eGFR, etc.), self-measured blood glucose (SMBG), blood pressure (BP), diabetes therapy, number of on-site and of telemedicine consultations. The mean values of all available measurements for HbA1c, SMBG, BP, weight, and body mass index (BMI) were calculated. Results: During the COVID-19 pandemic, the HbA1c values increased (6.78±0.77% to 6.96±0.87%, p<0.0001; + 0.18±0.67%), despite treatment intensification (p<0.01), while BMI and total cholesterol values slightly decreased (32.01±5.5 kg/m2 to 31.7±5.4 kg/m2, p<0.0001, and 178.1±40.8 mg/dl to 170.5±38.4 mg/dl, p<0.05). The deterioration of glycemic control (to HbA1c >7%) were rather seen in males (to 7.01±0.92%, p<0.0001), patients from rural areas (to 7.08±0.96%, p<0.001) and younger than 65 y.o. (to 7.05±0.82%, p<0.001). More male patients had a mean HbA1c increase of >0.5% during the COVID-19 pandemic (32.3% vs 21.5%, p<0.05). Patients who received more diabetes care visits through telemedicine had a more attenuated increase in HbA1c (6.79±0.80% to 6.90±0.83%, p<0.05 vs 6.76±0.72% to 7.08±0.92%, p<0.0001). Conclusions: The glycemic control slightly deteriorated during the COVID-19 pandemic (but with overall HbA1c within target), with certain patient categories being more affected. Diabetes care though telemedicine allowed the maintenance of the metabolic control.

Keywords: type 2 diabetes, COVID-19, telemedicine

Received: 19.10.2022
Accepted: 17.11.2022
Published: 27.11.2022

 
  PDF Download full text PDF
(375 KB)
     
 
How to cite
Onea CR, Erőss Á, Roiban AL, Cernea S. The metabolic control and laboratory evaluation in patients with type 2 diabetes during the COVID-19 pandemic and the impact of telemedicine: a single-center experience. Rev Romana Med Lab. 2023;31(1):43-50. DOI:10.2478/rrlm-2023-0002